Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin LymphomaRobert Chen, Stephen J. Forman, Tanya Siddiqi et al.|Transplantation and Cellular Therapy|2015Cited by 153
Results of a Phase II Trial of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCTRobert W. Chen, Stephen J. Forman, Joycelynne Palmer et al.|Blood|2014Cited by 14
Post Transplant Outcome of a Multicenter Phase II Study of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCTRobert Chen, Stephen J. Forman, Joycelynne Palmer et al.|Blood|2015Cited by 13